Prothena sells ATTR amyloidosis portfolio to Novo Nordisk for up to $1.2 billion

Shares of Prothena Corp. Plc /zigman2/quotes/204713496/composite PRTA +1.64% were up 1.3% in premarket trading on Monday after the company announced a deal to sell its ATTR amyloidosis portfolio to Novo Nordisk /zigman2/quotes/207193277/delayed DK:NOVO.B +1.72% in a $100 million deal that is worth up to $1.2 billion, based on milestones. ATTR amyloidosis is a rare disease that can cause a buildup of amyloid deposits in the body. One of the therapies in the portfolio is an experimental monoclonal antibody drug that has completed a Phase 1, open-label clinical trial. Prothena's stock has soared 393.2% so far this year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.16% is up 16.3%.

/zigman2/quotes/204713496/composite

Add to watchlist PRTA

Prothena Corp. PLC

US : U.S.: Nasdaq

$ 47.84

+0.77 +1.64%

Volume: 324,249

March 27, 2023 4:00p

P/E Ratio

N/A

Dividend Yield

N/A

Market Cap

$2.47 billion

Rev. per Employee

$424,449

/zigman2/quotes/207193277/delayed

Add to watchlist DK:NOVO.B

Novo Nordisk A/S Series B

DK : Denmark: OMX

kr. 1,067.00

+18.00 +1.72%

Volume: 1.56M

March 27, 2023 4:59p

P/E Ratio

43.67

Dividend Yield

1.16%

Market Cap

kr.2362.15 billion

Rev. per Employee

kr.3.25M

/zigman2/quotes/210599714/realtime

Add to watchlist SPX

S&P 500 Index

US : S&P US

3,977.53

+6.54 +0.16%

Volume: 0.00

March 27, 2023 5:00p